Clinical Trial Update: A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of remibrutinib in Japanese adults with chronic spontaneous urticaria inadequately controlled by H1 antihista…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2024-11-22